New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
08:01 EDTSTJSt. Jude Medical initiates EnligHTNment study of renal denervation
St. Jude Medical announced plans for a new landmark study that will evaluate whether renal denervation and medication can provide health benefits to patients beyond lowering high blood pressure. The EnligHTNment trial is the first large-scale study that will examine the long-term effects of renal denervation in patients who have uncontrolled hypertension to see if renal denervation also reduces the risk of major cardiovascular events such as heart attack, stroke and death. St. Jude Medical is currently conducting two additional renal denervation studies called EnligHTN I and EnligHTN II that are evaluating the EnligHTN system for hypertension. Results to-date from the EnligHTN I trial demonstrated that patients with drug-resistant hypertension treated with the St. Jude Medical EnligHTN system had a rapid and sustained drop in blood pressure. After thirty days, systolic blood pressure was rapidly reduced by an average of 28 mmHg that remained stable with a reduction of 26 mmHg points six months after treatment. This is an important finding as the risk of cardiovascular death drops by half with every systolic decrease of 20 mmHg. The EnligHTN II trial is being conducted at 40 sites in Europe and Australia and will enroll approximately 500 patients with uncontrolled hypertension. The study began enrollment in January 2013 to evaluate the reduction in systolic blood pressure at six months across all enrolled patients after having renal denervation, and within sub-groups with varying degrees of kidney functionality.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
08:00 EDTSTJSt. Jude Medical price target lowered to $47 from $51 at Canaccord
Subscribe for More Information
April 16, 2014
15:39 EDTSTJBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
10:00 EDTSTJSt. Jude Medical falls 4.3%
Subscribe for More Information
08:33 EDTSTJSt. Jude Medical sees total Q2 CRM sales $705M-$735M
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical sees FY14 consolidated adjusted EPS $3.95-$4.00
Subscribe for More Information
07:33 EDTSTJSt. Jude Medical sees Q2 consolidated adjusted EPS 99c-$1.01, consensus $1.00
Sees Q2 revenue $1.38B-$1.46B, consensus $1.44B.
07:31 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 96c, consensus 95c
Subscribe for More Information
April 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
09:23 EDTSTJBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use